0001570562-24-000030.txt : 20240223 0001570562-24-000030.hdr.sgml : 20240223 20240223202747 ACCESSION NUMBER: 0001570562-24-000030 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240221 FILED AS OF DATE: 20240223 DATE AS OF CHANGE: 20240223 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Avelar Rui CENTRAL INDEX KEY: 0001432063 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38381 FILM NUMBER: 24673300 MAIL ADDRESS: STREET 1: 1618 STATION STREET CITY: VANCOUVER STATE: A1 ZIP: V6A 1B6 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Evolus, Inc. CENTRAL INDEX KEY: 0001570562 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 461385614 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 520 NEWPORT CENTER DRIVE STREET 2: SUITE 1200 CITY: NEWPORT BEACH STATE: CA ZIP: 92660 BUSINESS PHONE: (949) 284-4555 MAIL ADDRESS: STREET 1: 520 NEWPORT CENTER DRIVE STREET 2: SUITE 1200 CITY: NEWPORT BEACH STATE: CA ZIP: 92660 4 1 wk-form4_1708738054.xml FORM 4 X0508 4 2024-02-21 0 0001570562 Evolus, Inc. EOLS 0001432063 Avelar Rui 520 NEWPORT CENTER DR. SUITE 1200 NEWPORT BEACH CA 92660 0 1 0 0 See Remarks 1 Common Stock 2024-02-21 4 A 0 13115 0 A 401712 D Common Stock 2024-02-22 4 S 0 1821 13.0812 D 399891 D Represents shares issuable on settlement of performance restricted stock units ("PSUs") granted to the reporting person in January 2023. The Issuer's Compensation Committee certified that the reporting person had achieved the set corporate development goal as of December 20, 2023. One-third of the PSU (4,372 shares) was delivered on February 21, 2024 after certification of the milestone being achieved. The remaining two-thirds will vest annually on the anniversary of December 20, 2023 provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the PSUs. Chief Medical Officer & Head of Research and Development /s/ Jeffrey J. Plumer, as attorney-in-fact for Rui Avelar 2024-02-23